UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

SCHEDULE 14A

(Rule 14a-101)

Information Required in Proxy Statement Schedule 14A Information

Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No.)

Filed by the Registrant ⊠			
Filed by a Party other than the Registrant □			
Check the appropriate box:			
	Preliminary Proxy Statement		
	Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2))		
	Definitive Proxy Statement		
\boxtimes	Definitive Additional Materials		
	Soliciting Material Pursuant to §240.14a-12		
	CULLINAN THERAPEUTICS, INC. (Name of Registrant as Specified in its Charter)		
	(Name of Person(s) Filing Proxy Statement, if other than the Registrant)		
Payment of Filing Fee (Check the appropriate box):			
\boxtimes	No fee required.		
	Fee paid previously with preliminary materials.		
	Fee computed on table in exhibit required by Item 25(b) per Exchange Act Rules 14a-6(i)(1) and 0-11		



CULLINAN THERAPEUTICS, INC.

2024 Annual Meeting Vote by June 25, 2024 11:59 PM ET



V51961-P05688

ONE MAIN STREET SUITE 1350 CAMBRIDGE, MA 02142

You invested in CULLINAN THERAPEUTICS, INC. and it's time to vote!

You have the right to vote on proposals being presented at the Annual Meeting. This is an important notice regarding the availability of proxy materials for the stockholder meeting to be held on June 26, 2024 at 10:00 a.m., Eastern Time.

Get informed before you vote

View the Notice and Proxy Statement and Annual Report online OR you can receive a free paper or email copy of the material(s) by requesting prior to June 12, 2024. If you would like to request a copy of the material(s) for this and/or future stockholder meetings, you may (1) visit www.ProxyVote.com, (2) call 1-800-579-1639 or (3) send an email to sendmaterial@proxyvote.com. If sending an email, please include your control number (indicated below) in the subject line. Unless requested, you will not otherwise receive a paper or email copy.



For complete information and to vote, visit www.ProxyVote.com

Control #

Vote Virtually at the Meeting*

June 26, 2024 10:00 a.m., Eastern Time

Virtually at: www.virtualshareholdermeeting.com/CGEM2024

Smartphone users

Point your camera here and vote without entering a control number



^{*}Please check the meeting materials for any special requirements for meeting attendance.

THIS IS NOT A VOTABLE BALLOT

This is an overview of the proposals being presented at the upcoming stockholder meeting. Please follow the instructions on the reverse side to vote these important matters.

Voting Items		Recommends
1.	Election of the following individuals nominated to serve as Class I directors, for a three-year term ending at the annual meeting of stockholders to be held in 2027:	
	Nominees:	⊘ For
	01) Anne-Marie Martin, Ph.D. 02) David Meek	
2.	Proposal to ratify the appointment of KPMG LLP as Cullinan Therapeutics' independent registered public accounting firm for the fiscal year ending December 31, 2024.	⊘ For
NO mee	TE: The Board of Directors will consider and act upon any other business as may properly come before the annual eting or any adjournment or postponement thereof.	

V51962-P05688

Prefer to receive an email instead? While voting on www.ProxyVote.com, be sure to click "Delivery Settings".